Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Holding AMGN?
Track your performance easily
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$249.70 - $346.85
Previous Close$321.33
Volume1.55M
Average Volume (3M)1.94M
Market Cap
$172.66B
Enterprise Value$226.00B
Total Cash (Recent Filing)$9.30B
Total Debt (Recent Filing)$62.65B
Price to Earnings (P/E)55.4
Beta0.51
Next Earnings
Oct 30, 2024EPS Estimate
$5.11Last Dividend Ex-Date
Aug 16, 2024Dividend Yield2.76%
Share Statistics
EPS (TTM)5.80
Shares Outstanding537,329,220
10 Day Avg. Volume1,528,086
30 Day Avg. Volume1,935,107
Standard Deviation0.07
R-Squared0.20
Alpha0.00598
Financial Highlights & Ratios
Price to Book (P/B)29.13
Price to Sales (P/S)5.59
Price to Cash Flow (P/CF)17.60
P/FCF Ratio14.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.31
Enterprise Value/Gross Profit11.45
Enterprise Value/Ebitda18.97
Forecast
1Y Price Target
$340.89Price Target Upside5.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Amgen News
Bulls Say, Bears Say
Bulls Say
Financial OutlookManagement's decision to raise FY23 revenue guidance by 4.4% following Horizon Therapeutics signals growing confidence in the company's financial performance and future growth prospects.
Obesity Drug MarketPositive results from MariTide's Phase 2 obesity data could unlock a mega market opportunity, potentially leading to a significant re-rating of shares as both obesity and non-obesity revenue opportunities are realized.
Pharmaceutical PerformanceUplizna's demonstrated efficacy in key subgroups and its favorable six-month dosing schedule could make it a preferred treatment option, enhancing its market potential significantly.
Bears Say
Competitive LandscapeAmgen's late-stage pipeline lacks near-term revenue-makers.
Patent ExpirationsThe top three best-selling drugs that make up approximately 40% of FY22 sales are facing the expiry of their patents in the US.
Pipeline EfficacyBoth therapies appear less efficacious than competing, approved products in their respective indications.
---
Ownership Overview
0.20% Insiders
21.14% Mutual Funds
1.55% Other Institutional Investors
50.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $249.70 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Oct 30, 2024 which is in 11 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 06, 2024. The company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $4.985 by -$0.015.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 2.76%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $5.11.
How many shares outstanding does Amgen have?
Amgen has 537,329,200 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.97 in its last earnings report, missing expectations of $4.985. Following the earnings report the stock price went down -5.002%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 5B.
---
Amgen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$340.89 (5.98% Upside)
$340.89 (5.98% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 231.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.37%
12-Months-Change
Fundamentals
Return on Equity
49.27%
Trailing 12-Months
Asset Growth
0.71%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q2 2024
0:00 / 0:00
---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$340.89
▲(5.98% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
25/32 ratings generated profit
1 Year Average Return
+15.17%
reiterated a buy rating 4 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 78.13% of your transactions generating a profit, with an average return of +15.17% per trade.
---